NEW YORK (GenomeWeb News) – Pressure BioSciences said in a regulatory document on Tuesday that it has entered into a securities purchase agreement, raising a little more than $1.2 million.

Pressure Bio entered into the agreement on Jan. 29 with various accredited investors to sell them an aggregate of 4,875 units at $250 per unit, the company said in a document filed with the US Securities and Exchange Commission. Purchasers included existing and new investors in the company and members of its board.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.